Grufity logoGrufity logo

Intellia Therapeutics Inc Stock Research

NTLA

38.30USD+1.12(+3.01%)Market Closed

Market Summary

USD38.30+1.12
Market Closed
3.01%

NTLA Alerts

NTLA Stock Price

NTLA RSI Chart

NTLA Valuation

Market Cap

3.3B

Price/Earnings (Trailing)

-7.04

Price/Sales (Trailing)

64.01

Price/Free Cashflow

-9.62

NTLA Price/Sales (Trailing)

NTLA Profitability

Return on Equity

-38.38%

Return on Assets

-31.19%

Free Cashflow Yield

-10.4%

NTLA Fundamentals

NTLA Revenue

Revenue (TTM)

52.1M

Revenue Y/Y

5.59%

Revenue Q/Q

2.31%

NTLA Earnings

Earnings (TTM)

-474.2M

Earnings Y/Y

-39.6%

Earnings Q/Q

-0.16%

Price Action

52 Week Range

32.4478.58
(Low)(High)

Last 7 days

-5.5%

Last 30 days

-1.6%

Last 90 days

9.5%

Trailing 12 Months

-46.8%

NTLA Financial Health

Current Ratio

9.61

NTLA Investor Care

Shares Dilution (1Y)

16.94%

Diluted EPS (TTM)

-6.16

Peers (Alternatives to Intellia Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
298.0B
1.4B
-3.25% 8.54%
-148.7
210.43
20.37% -37.45%
279.9B
58.1B
4.88% 1.38%
23.64
4.82
3.30% 2.55%
87.7B
12.2B
9.61% 20.63%
20.21
7.2
-24.26% -46.28%
80.8B
8.9B
6.80% 24.91%
24.32
9.05
17.91% 41.84%
23.5B
1.0B
-5.53% 16.05%
-20.81
22.69
22.88% -32.64%
11.5B
933.0M
2.93% 61.85%
-16.28
12.27
32.93% -67.99%
10.1B
1.9B
-9.77% 22.96%
13.92
5.23
14.88% 52.86%
MID-CAP
4.2B
504.0K
-19.59% 144.55%
-14.38
2.5K
-66.53% -22.12%
2.6B
363.3M
-18.37% -45.49%
-3.74
7.28
3.39% -55.81%
2.6B
204.0M
1.49% -34.21%
-4.68
12.78
13.30% 13.44%
2.3B
12.4M
-15.06% -52.42%
-3.05
181.9
- -27.34%
SMALL-CAP
1.7B
214.2M
4.81% 93.98%
20.42
7.92
52.10% 110.42%
412.2M
151.9M
1.98% -27.23%
-3.44
2.71
96.19% 40.75%
28.6M
-
145.52% 1270.00%
-0.67
19.11
-77.61% 7.22%
3.1M
94.6M
-20.08% -11.44%
-0.01
0.03
34.30% -80.65%

Financials for Intellia Therapeutics

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue1.4%52,121,00051,402,00045,340,00037,860,00033,053,000
  S&GA Expenses1.7%90,306,00088,788,00085,354,00079,905,00071,096,000
  R&D Expenses7.4%419,979,000391,106,000354,941,000323,626,000229,807,000
EBITDA--60,652,000----
EBITDA Margin--1.83----
EBT Margin--2.04----
Net Income-7.3%-474,186,000-442,016,000-400,431,000-368,559,000-267,892,000
Net Income Margin-5.8%-9.10-8.60-8.83-9.73-
Free Cahsflow-11.7%-346,845,000-310,583,000-297,380,000-264,228,000-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets40.2%1,5201,0841,1101,2031,294
  Current Assets41.7%1,217859895875769
    Cash Equivalents270.8%524141148133123
  Net PPE5.0%28.0027.0026.0024.0021.00
  Current Liabilities-3.5%127131124126126
Shareholder's Equity49.8%1,2368258819541,040
  Retained Earnings-10.7%-1,177-1,063-950-849-703
  Additional Paid-In Capital27.5%2,4201,8981,8411,8121,746
Accumulated Depreciation-26.00----
Shares Outstanding13.7%87.0077.0076.0076.0074.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-11.8%-333-298-284-252-225
  Share Based Compensation12.4%91.0081.0072.0059.0047.00
Cashflow From Investing411.4%16031.00-415-477-550
Cashflow From Financing633.5%58379.00724725737

Risks for NTLA

What is the probability of a big loss on NTLA?

100%


Probability that Intellia Therapeutics stock will be more than 20% underwater in next one year

95%


Probability that Intellia Therapeutics stock will be more than 30% underwater in next one year.

72.3%


Probability that Intellia Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NTLA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Intellia Therapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for NTLA

Cumulative Returns on NTLA

10.1%


5-Year Cumulative Returns

46.0%


3-Year Cumulative Returns

What are the long-term rolling returns for NTLA?

FIve years rolling returns for Intellia Therapeutics.

Annualized Returns

Which funds bought or sold NTLA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
reduced
-2.06
-562,457
882,543
-%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-23.38
-890,000
815,000
-%
2023-02-28
Voya Investment Management LLC
added
2.76
-2,192,670
3,910,330
0.01%
2023-02-27
Parallax Volatility Advisers, L.P.
added
541
654,424
872,424
-%
2023-02-24
NATIXIS
reduced
-8.38
-104,930
133,070
-%
2023-02-21
MACQUARIE GROUP LTD
reduced
-2.34
-492,000
698,000
-%
2023-02-16
AXXCESS WEALTH MANAGEMENT, LLC
reduced
-21.7
-518,469
494,531
0.04%
2023-02-15
Capital Impact Advisors, LLC
reduced
-10.45
-212,503
373,497
0.36%
2023-02-15
Utah Retirement Systems
unchanged
-
-198,034
327,966
-%
2023-02-15
Steward Partners Investment Advisory, LLC
reduced
-12.15
-60,871
73,129
-%

1–10 of 42

Latest Funds Activity

Are funds buying NTLA calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own NTLA
No. of Funds

Intellia Therapeutics News

MarketBeat

William Blair Weighs in on Intellia Therapeutics, Inc.'s Q1 2023 ....

MarketBeat,
69 minutes ago

InvestorPlace

Brownstone Research

The Motley Fool

Investors Chronicle

Schedule 13G FIlings of Intellia Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.28%
7,810,226
SC 13G/A
Jan 25, 2023
blackrock inc.
8.7%
7,254,921
SC 13G
Feb 14, 2022
nikko asset management americas, inc.
3.70%
2,753,903
SC 13G/A
Feb 11, 2022
regeneron pharmaceuticals, inc.
4.98%
3,702,995
SC 13G/A
Feb 09, 2022
ark investment management llc
10.64%
7,916,882
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G
Feb 04, 2022
sumitomo mitsui trust holdings, inc.
3.70%
2,753,903
SC 13G/A
Feb 03, 2022
blackrock inc.
7.6%
5,620,376
SC 13G/A
Nov 26, 2021
ark investment management llc
10.40%
7,642,452
SC 13G/A

NTLA Fair Value

Intellia Therapeutics fair value in different scenarios

The table shows the Fair Value estimates for Intellia Therapeutics for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

0.05

-99.87%

0.11

-99.71%

0.32

-99.16%

0.66

-98.28%

0.99

-97.42%
Current Inflation

0.04

-99.90%

0.10

-99.74%

0.29

-99.24%

0.58

-98.49%

0.86

-97.75%
Very High Inflation

0.04

-99.90%

0.09

-99.77%

0.24

-99.37%

0.48

-98.75%

0.71

-98.15%

Historical Intellia Therapeutics Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Intellia Therapeutics

View All Filings
Date Filed Form Type Document
Mar 24, 2023
8-K
Current Report
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 03, 2023
4
Insider Trading
Mar 02, 2023
8-K
Current Report
Feb 23, 2023
10-K
Annual Report

Latest Insider Trading transactions for NTLA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-02
BASTA JAMES
sold
-47,741
43.88
-1,088
evp, general counsel
2023-03-01
Hicks Derek
acquired
-
-
23,558
evp, chief business officer
2023-03-01
Lebwohl David
acquired
-
-
30,674
evp, chief medical officer
2023-03-01
Clark Eliana
acquired
-
-
30,673
evp, chief technical officer
2023-03-01
LEONARD JOHN M
acquired
-
-
91,036
president and ceo
2023-03-01
Sepp-Lorenzino Laura
acquired
-
-
29,938
evp, chief scientific officer
2023-03-01
Goddard Glenn
acquired
-
-
27,484
evp, chief financial officer
2023-03-01
BASTA JAMES
acquired
-
-
36,808
evp, general counsel
2023-01-05
Sepp-Lorenzino Laura
sold
-89,658
38.4802
-2,330
evp, chief scientific officer
2023-01-04
Hicks Derek
sold
-67,424
37.21
-1,812
evp, chief business officer

1–10 of 50

John M. Leonard
480
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

NTLA Income Statement

2022-12-31
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]   
Collaboration revenue$ 52,121$ 33,053$ 57,994
Type of Revenue [Extensible List]us-gaap:LicenseAndServiceMemberus-gaap:LicenseAndServiceMemberus-gaap:LicenseAndServiceMember
Operating expenses:   
Research and development$ 419,979$ 229,807$ 150,408
General and administrative90,30671,09644,169
Total operating expenses510,285300,903194,577
Operating loss(458,164)(267,850)(136,583)
Other (expense) income, net:   
Interest income8,5421,2832,352
Loss from equity method investments(11,079)(1,325)0
Change in fair value of contingent consideration(13,485)00
Total other (expense) income, net(16,022)(42)2,352
Net loss$ (474,186)$ (267,892)$ (134,231)
Net Loss Per Share, Basic$ (6.16)$ (3.78)$ (2.40)
Net Loss Per Share, Diluted$ (6.16)$ (3.78)$ (2.40)
Weighted average shares outstanding, basic76,97270,89455,987
Weighted average shares outstanding, diluted76,97270,89455,987
Other comprehensive loss:   
Unrealized loss on marketable securities$ (1,637)$ (2,126)$ (260)
Other comprehensive loss from equity method investment(3,192)(507)0
Comprehensive loss$ (479,015)$ (270,525)$ (134,491)

NTLA Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current Assets:  
Cash and cash equivalents$ 523,506$ 123,406
Marketable securities669,116625,282
Accounts receivable ($0.3 million and $0.1 million from related party)3,7682,031
Prepaid expenses and other current assets20,40718,584
Total current assets1,216,797769,303
Marketable securities - noncurrent69,338337,361
Property and equipment, net27,92120,968
Operating lease right-of-use assets133,07679,143
Equity method investment32,45558,131
Investments and other assets40,52729,558
Total Assets1,520,1141,294,464
Current Liabilities:  
Accounts payable5,1549,653
Accrued expenses ($1.6 million and $0 million due to related party)60,87643,309
Current portion of operating lease liability16,6859,112
Current portion of deferred revenue ($19.9 million and $34.2 million from related party)43,83963,759
Total current liabilities126,554125,833
Deferred revenue, net of current portion ($0 million and $19.9 million from related party)19,93263,476
Long-term operating lease liability114,01864,911
Contingent consideration liability24,0260
Commitments and contingencies (Note 8)
Stockholders’ Equity:  
Common stock, $0.0001 par value; 120,000,000 shares authorized; 87,103,007 and 74,485,883 shares issued and outstanding at December 31, 2022 and 2021, respectively97
Additional paid-in capital2,420,2231,745,870
Accumulated other comprehensive income(7,461)(2,632)
Accumulated deficit(1,177,187)(703,001)
Total stockholders’ equity1,235,5841,040,244
Total Liabilities and Stockholders’ Equity$ 1,520,114$ 1,294,464